April 16 (Reuters) - Beigene Ltd ::BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING.BEIGENE LTD - PAMIPARIB WAS SHOWN TO BE GENERALLY WELL TOLERATED.BEIGENE LTD - LOOK FORWARD TO ADVANCING PAMIPARIB'S DEVELOPMENT IN CHINA AS WELL AS INITIATING A GLOBAL PHASE 3 TRIAL.BEIGENE - IN PATIENTS WITH OVARIAN, BREAST CANCER, PRELIM RESULTS SUPPORT RECOMMENDED PAMIPARIB DOSING REGIMEN, DEMONSTRATED ANTITUMOR ACTIVITY.BEIGENE-SAW NO DOSE-LIMITING TOXICITIES, FOUND PAMIPARIB TO BE GENERALLY WELL TOLERATED AMONG THE PRE-TREATED PATIENTS WITH OVARIAN, BREAST CANCERS.
Full Article
Jan 16 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES PROPOSED PUBLIC OFFERING.BEIGENE LTD - PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE.BEIGENE LTD - BEIGENE INTENDS TO OFFER AND SELL $650 MILLION OF ITS ADSS, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES.
Full Article
Jan 9 (Reuters) - Beigene Ltd ::BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB.BEIGENE LTD - BOEHRINGER INGELHEIM WILL MANUFACTURE TISLELIZUMAB IN CHINA UNDER AN EXCLUSIVE MULTI-YEAR ARRANGEMENT, WITH CONTRACT EXTENSION POSSIBLE.BEIGENE LTD - CO ALSO OBTAINED CERTAIN PREFERRED RIGHTS FOR FUTURE CAPACITY EXPANSION BY BOEHRINGER INGELHEIM IN CHINA.
Full Article
Jan 8 (Reuters) - Beigene Ltd ::BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION.BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD..BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE.BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS.BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATI'S SITRAVATINIB IN ASIA.
Full Article
Nov 13 (Reuters) - Beigene Ltd ::Beigene reports third quarter 2017 financial results.Beigene Ltd - qtrly net income attributable to common shareholders per ads, diluted $2.54.
Full Article
Beigene Ltd : Beigene receives approval to initiate clinical trials in china with parp inhibitor BGB-290 .Received clinical trial application approval from China Food And Drug Administration (CFDA) to conduct clinical trials in China with BGB-290.
Full Article
Beigene Ltd : Beigene reports second quarter 2016 financial results . Qtrly net loss per ads $0.73 . Revenue for three months ended June 30, 2016 was $0.39 million, compared to $1.38 million for three months ended June 30, 2015 .Q2 earnings per share view $-0.68, revenue view $1.4 million -- Thomson Reuters I/B/E/S.
Full Article
Beigene Ltd : Qtrly loss per share $0.97 . Revenue for the three months ended march 31, 2016 was $0.68 million, compared to $1.38 million for the three months ended march 31, 2015 .Beigene reports first quarter 2016 financial results.
Full Article
Earnings vs. 
Estimates